Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Scopus

Scopus profile and journal metrics

This journal is indexed in Scopus. Use these metrics for a quick publishing snapshot, then open the Scopus page for the authoritative profile.

Scopus
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Indexed in Scopus since 2022
CiteScore 1.0
Indexed since 2022
First decision 7 Days
Submission to acceptance 45 Days
Acceptance to publication 14 Days
Acceptance rate 8%

SCImago

SCImago Journal Rank preview

Use SCImago when you want a quick visual view of the journal ranking profile and external discoverability signals.

Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) SCImago Journal & Country Rank

DOAJ

Directory of Open Access Journals listing

The DOAJ record is useful for readers, librarians, and authors who want a direct open-access directory entry for the journal.

DOAJ
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Open directory record
Original full research article

Characteristics of non-alcoholic fatty liver disease in Palestinian diabetics: A cross-sectional study

Published
2023-01-10
Pages
307 - 320
Full text

Keywords

  • Fatty liver disease
  • Diabetes mellites
  • Non-alcoholic fatty liver
  • hepatic steatosis index

Abstract

This cross-sectional study was performed to identify the factors associated with non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients in Nablus, Palestine, and decrease the burden of liver diseases. Patients with T2DM who visited primary healthcare clinics in Nablus from January to April 2022 were invited [n=508] to participate. A face-to-face interview was conducted, and medical reports were used to collect the pa-tient's details. The hepatic steatosis index (HSI) was calculated as an indicator of the possibil-ity of the presence of NAFLD. Ultrasound was used to diagnose fatty liver disease (FLD) as mild, moderate, and severe. 399 Patients completed participation, with a mean age of 56.1±10.4 years; 56.1% were males, 91.2% had an HSI score ≥36, and 8.8% had an HSI score of 30-36. Moreover, 3.8% were diagnosed with mild FLD, 42.1% with moderate FLD, and 3.8% with severe FLD. Compared to patients without fatty liver disease, severe FLD pa-tients were at higher risk of having increased cholesterol levels (OR=1.047), increased HSI (OR=1.32), and diabetic retinopathy (OR=7.074). Predictors for moderate FLD have in-creased cholesterol levels (OR=1.023), glycated hemoglobin (HbA1c) (OR=1.06), HSI (OR=1.21), and age (OR=1.071). Predictors for mild FLD have increased cholesterol levels (OR=1.02), HbA1c (OR=1.312), HSI (OR=1.102), and age (OR=1.047). Decreased levels of low-density lipoproteins were associated with decreased risk of mild (OR=0.982), moderate (OR=0.97), and severe (OR=0.955) FLD. Diabetes treatment regimen, the number of years diagnosed with diabetes, hypertension, high-density lipoprotein, and triglycerides levels were not associated with FLD. In conclusion, the prevalence of NAFLD among Palestinian T2DM patients was higher than the reported global prevalence. Several modifiable (weight, HbA1c, HSI score, total cholesterol, and low-density lipoprotein levels) and non-modifiable (age and diabetic retinopathy) factors were associated with NAFLD. This research recommends a screening program for the early detection of NAFLD among Palestinian people with diabetes using ultrasound.

Article history

Received
2022-05-19
Accepted
2023-01-10
بحث أصيل كامل

Characteristics of non-alcoholic fatty liver disease in Palestinian diabetics: A cross-sectional study

Published
2023-01-10
الصفحات
307 - 320
البحث كاملا

الكلمات الإفتتاحية

  • Fatty liver disease
  • Diabetes mellites
  • Non-alcoholic fatty liver
  • hepatic steatosis index

الملخص

This cross-sectional study was performed to identify the factors associated with non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients in Nablus, Palestine, and decrease the burden of liver diseases. Patients with T2DM who visited primary healthcare clinics in Nablus from January to April 2022 were invited [n=508] to participate. A face-to-face interview was conducted, and medical reports were used to collect the pa-tient's details. The hepatic steatosis index (HSI) was calculated as an indicator of the possibil-ity of the presence of NAFLD. Ultrasound was used to diagnose fatty liver disease (FLD) as mild, moderate, and severe. 399 Patients completed participation, with a mean age of 56.1±10.4 years; 56.1% were males, 91.2% had an HSI score ≥36, and 8.8% had an HSI score of 30-36. Moreover, 3.8% were diagnosed with mild FLD, 42.1% with moderate FLD, and 3.8% with severe FLD. Compared to patients without fatty liver disease, severe FLD pa-tients were at higher risk of having increased cholesterol levels (OR=1.047), increased HSI (OR=1.32), and diabetic retinopathy (OR=7.074). Predictors for moderate FLD have in-creased cholesterol levels (OR=1.023), glycated hemoglobin (HbA1c) (OR=1.06), HSI (OR=1.21), and age (OR=1.071). Predictors for mild FLD have increased cholesterol levels (OR=1.02), HbA1c (OR=1.312), HSI (OR=1.102), and age (OR=1.047). Decreased levels of low-density lipoproteins were associated with decreased risk of mild (OR=0.982), moderate (OR=0.97), and severe (OR=0.955) FLD. Diabetes treatment regimen, the number of years diagnosed with diabetes, hypertension, high-density lipoprotein, and triglycerides levels were not associated with FLD. In conclusion, the prevalence of NAFLD among Palestinian T2DM patients was higher than the reported global prevalence. Several modifiable (weight, HbA1c, HSI score, total cholesterol, and low-density lipoprotein levels) and non-modifiable (age and diabetic retinopathy) factors were associated with NAFLD. This research recommends a screening program for the early detection of NAFLD among Palestinian people with diabetes using ultrasound.

Article history

تاريخ التسليم
2022-05-19
تاريخ القبول
2023-01-10